BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Beats Expectations By $1.05 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) issued its quarterly earnings data on Thursday. The biotechnology company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $1.05, Briefing.com reports. The firm had revenue of $406.56 million for the quarter, compared to analysts’ expectations of $151.32 million. BioCryst Pharmaceuticals had a negative net margin of 1.46% and a negative return on equity of 4.24%. The firm’s revenue was up 209.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.13) EPS.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• BioCryst closed 2025 with strong ORLADEYO sales of $601.8M (up 38% YoY; 43% ex‑Europe) and launched ORLADEYO Pellets for ages 2–<12, which management expects to increase pediatric diagnosis and long‑term patient growth.
• Navenibart Phase 3 (Alpha Orbit) is recruiting well with ~145 patients expected by mid‑2026; Phase 2 showed ~90–92% mean attack reductions and a mean attack rate of 0.16/month, and the company is targeting a BLA submission by end‑2027 and approval in late‑2028.
• The company reported record non‑GAAP operating profit of $214M, ended 2025 with $337.5M in cash/investments and secured a $400M financing facility with Blackstone, highlighting strong liquidity and capital optionality.
• Early‑stage KLK5 inhibitor BCX‑17725 completed healthy‑volunteer dosing with favorable safety and epidermal distribution and is moving into patient cohorts (up to 12 in Part 4) with data expected by year‑end 2026, offering pipeline optionality but still early evidence.
• Management warns of a likely Q1 revenue dip due to reauthorization season and expects higher non‑GAAP R&D spend in 2026 (guidance OpEx $450–$470M) to complete navenibart Phase 3 and CMC work, which will raise near‑term operating expenses despite a goal to remain profitable.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock traded up $0.37 on Thursday, hitting $7.92. The stock had a trading volume of 4,191,781 shares, compared to its average volume of 4,347,615. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.31. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -158.42 and a beta of 0.83. The stock’s 50 day moving average is $7.10 and its 200-day moving average is $7.39.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 91,004 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $7.10, for a total value of $646,128.40. Following the completion of the transaction, the insider directly owned 416,152 shares of the company’s stock, valued at $2,954,679.20. This represents a 17.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders have sold 183,453 shares of company stock valued at $1,330,965. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Invesco Ltd. raised its position in shares of BioCryst Pharmaceuticals by 40.8% in the 4th quarter. Invesco Ltd. now owns 1,354,897 shares of the biotechnology company’s stock valued at $10,568,000 after purchasing an additional 392,521 shares in the last quarter. Mackenzie Financial Corp boosted its stake in BioCryst Pharmaceuticals by 16.6% during the 4th quarter. Mackenzie Financial Corp now owns 150,728 shares of the biotechnology company’s stock valued at $1,152,000 after acquiring an additional 21,411 shares during the last quarter. NewEdge Advisors LLC acquired a new position in BioCryst Pharmaceuticals during the 4th quarter worth $390,000. XTX Topco Ltd acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at about $133,000. Finally, Vestal Point Capital LP bought a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $17,550,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Citizens Jmp dropped their target price on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a research note on Wednesday, November 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, December 29th. Barclays dropped their price target on shares of BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 4th. Evercore assumed coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 price target on the stock. Finally, HC Wainwright boosted their price objective on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.64.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.